Prazer Therapeutics
PrivateLast Round
Series B
Apr 2, 2025
Total Funding Raised
$30.6M
Momentum Score
75 /100
Company Overview
Prazer Therapeutics is a biotechnology company developing innovative therapeutics for various intractable diseases using its proprietary targeted protein degradation (TPD) platform called SPiDEM.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Prazer Therapeutics Comps
Public and private peers based on sector, stage, and business model.
Prazer Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Apr 2, 2025 | ||||
| Series A | Dec 23, 2020 |
Key People
Founding team and executive leadership
Prazer Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| K2 Investment Partners | Series B |
| Smilegate Investment | Series B, Series A |
| Premier Partners | Series B |
| QUAD Investment Management | Series B |
| Company K Partners | Series B, Series A |
| Kiwoom Investment | Series B, Series A |
| Mirae Asset Capital | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 26, 2026
Grew 32% QoQ from 19 to 25 employees.
- Apr 18, 2026
Monthly visitors grew 91% MoM, reaching 7K.
Prazer Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Prazer Therapeutics's valuation, stock price, and market status.
